scholarly journals MiR-223 or miR-126 predicts resistance to dual antiplatelet therapy in patients with ST-elevation myocardial infarction

2021 ◽  
Vol 49 (6) ◽  
pp. 030006052110162
Author(s):  
Xiaojing Li ◽  
Qi Yao ◽  
Hanbin Cui ◽  
Jun Yang ◽  
Nan Wu ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Antiplatelet Therapy ◽  
Dual Antiplatelet Therapy ◽  
St Elevation Myocardial Infarction ◽  
Event Free Survival ◽  
Free Survival ◽  
St Elevation ◽  
Treatment Responses

Objective To explore the role of miR-223 and miR-126 in predicting treatment responses to dual antiplatelet therapy (DAPT) in patients with ST-elevation myocardial infarction (STEMI). Methods Plasma miR-223 and miR-126 levels were measured before treatment. Treatment responses and 2-year survival were determined. In vitro experiments were performed to explore the mechanism of action. Results Patients with resistance to DAPT had a lower level of miR-223 and miR-126. Cardiac-event-free survival was shorter in patients with lower miR-223 or miR-126 levels. MiR-223 and miR-126 independently predicted DAPT resistance. Modulating miR-223 or miR-126 in platelets in vitro significantly changed the response to clopidogrel by regulating platelet aggregation. Conclusion MiR-223 and miR-126 play a role in DAPT resistance and may provide potential biomarkers in patients with STEMI.

scholarly journals Pretreatment with dual antiplatelet therapy in patients with ST-elevation myocardial infarction

2017 ◽  
Vol 92 (2) ◽  
pp. E98-E105
Author(s):  
Matias B. Yudi ◽  
Omar Farouque ◽  
Nick Andrianopoulos ◽  
Andrew E. Ajani ◽  
Angela Brennan ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Antiplatelet Therapy ◽  
Dual Antiplatelet Therapy ◽  
St Elevation Myocardial Infarction ◽  
St Elevation

Incidence of dual antiplatelet therapy interruption within 1 year after primary percutaneous coronary intervention in patients with acute ST elevation myocardial infarction

2019 ◽  
Vol 96 (1131) ◽  
pp. 9-13
Author(s):  
Chor Cheung Tam ◽  
Jeffrey Lee ◽  
Ki Wan Chan ◽  
Cheung Chi Lam ◽  
Yiu Tung Wong ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Percutaneous Coronary Intervention ◽  
Antiplatelet Therapy ◽  
Primary Percutaneous Coronary Intervention ◽  
Dual Antiplatelet Therapy ◽  
Univariate Analysis ◽  
Coronary Intervention ◽  
St Elevation Myocardial Infarction ◽  
Percutaneous Coronary ◽  
St Elevation

BackgroundAfter primary percutaneous coronary intervention (PPCI) in patients with acute ST elevation myocardial infarction (STEMI), dual antiplatelet therapy (DAPT) is recommended to continue for 1 year. Occasionally, DAPT interruption may be required due to bleeding issues or unplanned surgical procedures.ObjectiveTo systematically evaluate the incidence of DAPT interruption within 1 year after PPCI.Methods and resultsThis was a single-centre, retrospective registry study. Consecutive patients with STEMI who underwent PPCI from 2013 to 2017 (N=538) were recruited into the analysis. The primary outcome was the incidence of interruption of DAPT within 1 year from the index PPCI. Secondary outcomes included incidence of bleeding in 1 year and prevalence of high bleeding risk (HBR) criteria at index presentation. Within 1 year, 17.1% (84/490) of post-PPCI survivors needed DAPT interruption and 7.1% (35/490) had major bleeding (Bleeding Academic Research Consortium type 3 or 5). At index presentation, HBR criteria were present in 36.1% (194/538) of patients. On univariate analysis, age, female gender, anaemia, anticoagulation, diabetes, hypertension and being a non-smoker were associated with DAPT interruption. On multivariate analysis, age was the only independent factor to predict DAPT interruption.ConclusionDAPT interruption was not uncommon after PPCI in patients with STEMI particularly in the elderly. This has implication on stent selection during PPCI, and further studies are required to investigate which type of stent may best suit our real-life patients with STEMI.

Sign in / Sign up

Export Citation Format

Share Document